The newly issued patent, titled ‘genetically modified cells and uses thereof,' fortifies Cartherics' proprietary stance on multiple development candidates within its pipeline.
This patent specifically covers stem cells engineered with Cartherics’ chimeric antigen receptor (CAR) targeting tumour-associated glycoprotein-72 (TAG-72).
It also extends protection to allogeneic (off-the-shelf) immune cell products derived from these stem cells.
TAG-72 is prominently expressed in various adenocarcinomas, including ovarian and gastric cancers.
Securing this patent marks a significant milestone in advancing new treatments for these cancers and bolsters Cartherics’ extensive intellectual property portfolio.
Cartherics' initial focus is on relapsed or refractory ovarian cancer, with over 90% of these tumours testing positive for TAG-72.
Prof. Alan Trounson AO, Cartherics’ CEO, stated, “Cartherics has made significant investments to secure robust patent protection for our technology platform.
"The issuance of this European patent reinforces the foundation for developing and commercializing our products, particularly our lead candidate, CTH-401."
The company has demonstrated that CTH-401 is very effective in killing ovarian cancer cells in both tissue culture and animal models, with initiation of the first clinical trial planned for early 2025.